Back to Search
Start Over
Lambert-Eaton Myasthenic Syndrome Caused by Atezolizumab in a Patient with Small-cell Lung Cancer
- Source :
- Internal medicine (Tokyo, Japan). 61(11)
- Publication Year :
- 2021
-
Abstract
- We herein report a 74-year-old man who developed Lambert-Eaton myasthenic syndrome (LEMS) during atezolizumab treatment for extensive-stage small-cell lung cancer. He was started on maintenance immunotherapy with atezolizumab every three weeks after four cycles of atezolizumab plus carboplatin plus etoposide combination therapy. After 13 cycles of maintenance atezolizumab therapy, he complained of muscular weakness and fatigue. Findings from a nerve conduction study and positive findings for anti-P/Q-type voltage-gated calcium channel antibody resulted in a diagnosis of LEMS. This was a rare case of LEMS as a neurological immune-related adverse event induced by atezolizumab therapy.
- Subjects :
- Male
medicine.medical_specialty
Lung Neoplasms
Combination therapy
Antibodies, Monoclonal, Humanized
Gastroenterology
chemistry.chemical_compound
Atezolizumab
Internal medicine
Internal Medicine
medicine
Humans
Adverse effect
Lung cancer
Etoposide
Aged
medicine.diagnostic_test
business.industry
General Medicine
medicine.disease
Small Cell Lung Carcinoma
Carboplatin
Lambert-Eaton Myasthenic Syndrome
chemistry
Nerve conduction study
business
Lambert-Eaton myasthenic syndrome
medicine.drug
Subjects
Details
- ISSN :
- 13497235
- Volume :
- 61
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Internal medicine (Tokyo, Japan)
- Accession number :
- edsair.doi.dedup.....d9d7a2fc74f6822a987ee9c38de1e74e